Comprehensive, up-to-date information on HIV/AIDS treatment, prevention, and policy from the University of California San Francisco

Use of a ritonavir-boosted protease inhibitor

Inclusion of at least 2 active antiretroviral drugs (ARVs)

Use of an integrase inhibitor (eg, raltegravir)

Viral tropism

a. It may enhance NNRTI efficacy, in vitro.

b. It is associated with high-level NRTI resistance.

c. It is associated with high-level integrase inhibitor resistance.

d. Choices a and b

M184V

TAM 1 pathway (41, 210, 215)

TAM 2 pathway (67, 70, 219)

K103N

a. It should include a ritonavir-boosted protease inhibitor.

b. It should include 1 or more NRTIs.

c. It should be based on genotype and phenotype test results.

d. It should be based on tropism testing, if treatment with a CCR5 antagonist is being considered.

e. Choices c and d